Abstract: SB202190 is a well-known p38 mitogen-activated protein kinase (MAPK) inhibitor that has been historically utilized as an essential component in the culture medium for human colorectal organoids. While its inclusion was initially based on empirical screening to enable the long-term expansion of normal and neoplastic epithelial organoids, recent evidence highlights its complex and often detrimental off-target effects. In the context of oncology and cancer research, SB202190 significantly alters intracellular signaling, most notably by amplifying Erk1-2 signaling through BRAF/CRAF dimerization and stabilizing the epidermal growth factor receptor (EGFR). Furthermore, it exhibits paradoxical effects in colorectal cancer (CRC) models, acting as an Erk1-2 agonist in BRAF wild-type cells while inhibiting Erk1-2 in BRAF-mutated cells. At standard culture concentrations, SB202190 also inhibits several other kinases, including GSK3β, CK1δ, RIPK2, and GAK, leading to artificial β-catenin accumulation, altered immune responses, and induced autophagy. Consequently, while SB202190 has been a legendary component in organoid derivation, its pleiotropic activities introduce significant experimental biases, necessitating its careful reevaluation or omission in specific short-term oncological assays and drug screenings.
1. Introduction
The development of specific culture media has revolutionized oncology research by enabling the indefinite in vitro expansion of human primary normal and pathological epithelial organoids. Since the pioneering establishment of human colorectal organoid cultures in 2011, the p38 inhibitor SB202190 has been a fundamental, yet controversial, component of the standard culture medium [1]. Originally identified through empirical screening, SB202190 was included to suppress negative signaling pathways and promote the long-term propagation of colon crypts [1]. However, as the application of patient-derived colorectal cancer (CRC) organoids expands in precision medicine and high-throughput drug screening, the chronic activation of agonist and antagonist signals by medium components like SB202190 has come under scrutiny. This compound forces organoid cells into constrained signaling pathways, creating highly artificial microenvironments that are often overlooked in experimental approaches [1].
2. Pharmacological Activity
SB202190 is primarily classified as a p38 MAPK inhibitor, a kinase involved in cellular stress and inflammatory responses [1]. In the context of colorectal organoid cultures, the pharmacological inhibition of p38 by SB202190 forces colorectal stem cells to differentiate toward enterocytes. A direct consequence of this activity is the complete disappearance of secretory populations, specifically Goblet and enteroendocrine cells [1]. Interestingly, the absence of these secretory populations does not enhance the overall viability of the organoids; rather, it compromises the physiological development of a multi-population organoid, inducing an undesirable biological effect [1]. Despite its classification, the primary beneficial pharmacological activity of SB202190 in these cultures is actually off-target: it stabilizes epidermal growth factor receptor (EGFR) signaling and reduces its degradation, thereby promoting cell survival and proliferation [1].
3. Molecular Mechanism of Action
The molecular mechanism of SB202190 extends far beyond its canonical role as a p38 inhibitor, exhibiting a complex profile of off-target kinase modulations that profoundly impact cellular biochemistry:
Erk1-2 Signaling Amplification: The fundamental activity of SB202190 on colorectal organoids is the amplification of Erk1-2 (extracellular signal-regulated kinase 1-2) signaling [1]. This agonist activity does not rely solely on EGFR stabilization but is driven by the drug's ability to induce increased BRAF/CRAF dimerization [1]. SB202190 mimics the BRAF inhibitor Dabrafenib, resulting in a well-documented paradox: it acts as an Erk1-2 agonist in BRAF wild-type cells, but functions as an Erk1-2 inhibitor in BRAF-mutated cells [1].
Wnt/β-Catenin Pathway Modulation: At a concentration of 1 µM—which is significantly lower than the 3–10 µM typically used in organoid cultures—SB202190 inhibits GSK3β and CK1δ. The inhibition of these specific kinases prevents the degradation of β-catenin, leading to its intracellular accumulation and the subsequent artificial amplification of Wnt signaling [1].
Additional Kinase Inhibition and Autophagy: Low-dose SB202190 also inhibits RIPK2 (which modulates immune responses), GAK (involved in clathrin-mediated endocytosis and mitophagy), and MLK2/MAP3K10 as well as MLK3/MAP3K11 (direct modulators of the Jun pathway) [1]. Furthermore, at a concentration of 10 µM, SB202190 actively induces autophagy and lysosomal biogenesis by activating the PPP3/calcineurin signaling pathway [1].
4. Structure-Activity Relationship (SAR)
While the provided literature does not detail specific chemical modifications or the classical Structure-Activity Relationship (SAR) of the SB202190 molecule, the pharmacological data strongly indicate a broad and complex kinase binding profile. The ability of SB202190 to bind and inhibit p38 MAPK while simultaneously inducing conformational changes that stabilize BRAF/CRAF dimers demonstrates that its structural pharmacophore interacts with multiple distinct kinase domains [1]. Furthermore, its off-target affinity for GSK3β, CK1δ, RIPK2, and GAK at very low concentrations (1 µM) highlights a lack of strict target selectivity, which is a critical structural consideration when utilizing this compound as a pharmacological probe in complex biological systems [1].
5. Current Limitations
The use of SB202190 in oncology research, particularly in 3D organoid models, presents several severe limitations and experimental biases. Because of its paradoxical effect on the Erk1-2 pathway, SB202190 must absolutely not be used with BRAF-mutated CRC organoids, as it will artificially inhibit Erk1-2 signaling and misrepresent the tumor's true biological behavior [1]. Additionally, its broad off-target effects significantly impact cell signaling, metabolism, oxidative stress, and immunological responses [1]. By forcing the differentiation of stem cells toward enterocytes and eliminating secretory cells, SB202190 prevents the establishment of a physiologically accurate, multi-population tumor microenvironment. These extremely artificial conditions are often overlooked and can severely bias the results of high-throughput drug screenings, potentially creating artifactual resistance or sensitization to specific oncological drugs that do not reflect the actual patient condition [1].
6. Future Perspectives
To improve the reliability of patient-derived organoids in precision oncology and drug discovery, the formulation of culture media must be critically reevaluated. Future research protocols should strongly consider omitting SB202190 from short-term tests, drug screenings, and any studies involving secretory cells or immune system interactions [1]. Evidence suggests that the beneficial effects of SB202190 can be effectively replaced; for instance, substituting SB202190 with growth factors like FGF2 and IGF1 has been found to be even more effective for colorectal organoid culture without the associated off-target toxicity [1]. Moving forward, the development of more focused, reliable, and defined culture conditions that exclude pleiotropic inhibitors like SB202190 will be essential for translating organoid-based discoveries into valid clinical applications [1].
